Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

NewAmsterdam Pharma Co N.V. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer Naarden, the Netherlands and Miami, USA; August 14, 2023 - NewAmsterdam Pharma Company N.V. , a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol , for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointment of William “BJ” Jones as the company's first Chief Commercial Officer , effective August 14, 2023. Mr. Jones brings 30 years of commercial and launch experience in the U.S. and globally, with particular experience in driving mass market product launch strategies for ...",
"NewAmsterdam Pharma Company N.V. Corporate Presentation"
08/07/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights"
08/07/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS",
"MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements as at June 30, 2023 and for the six months ended June 30, 2023 and 2022 and the related notes to those financial statements included in Exhibit 99.1 to the Report on Form 6-K of which this exhibit forms a part. Our unaudited condensed consolidated financial statements are presented in Euro and have been prepared in accordance with IAS 34. Financial statements prepared in accordance with IFRS may differ in material respects from generally accepted accounting principles in other jurisdictions, including U.S. GAAP but which our mana..."
07/26/2023 6-K Quarterly results
05/31/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Convening Notice for the 2023 Annual General Meeting of Shareholders",
"Convening Notice for the 2023 Annual General Meeting of Shareholders"
05/23/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023"
05/08/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Highlights"
04/24/2023 6-K Quarterly results
04/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors Naarden, the Netherlands and Miami, USA; April 3, 2023 - NewAmsterdam Pharma Company N.V. , a clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases, today announced the appointment of Janneke van der Kamp as an independent director to its Board of Directors. Ms. van der Kamp is an established pharmaceutical leader, with two decades of experience launching and growing key brands across several therapeutic areas, including cardiovascular disease. “We are delighted to welcome Janneke to our Board of Directors as we rapidly advance our registration-enabling clinical trials of obicetrapib and prepare for key clinical and regulatory milestones i..."
03/31/2023 6-K Quarterly results
03/07/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "NewAmsterdam Pharma Company N.V. Corporate Presentation",
"NewAmsterdam Pharma Company N.V. Corporate Presentation"
02/14/2023 6-K Quarterly results
02/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"NewAmsterdam Pharma Appoints John W. Smither to its Board of Directors Naarden, the Netherlands and Miami, USA; February 6, 2023 - NewAmsterdam Pharma Company N.V. , a clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases, today announced the appointment of John W. Smither as an independent director to its Board of Directors. Mr. Smither will also serve as chair of NewAmsterdam Pharma's Audit Committee. “We are so pleased to welcome John to the NewAmsterdam Board of Directors,” said Michael Davidson, M.D., chief executive officer of NewAmsterdam Pharma. “His extensive experience in operational and strategic leadership roles across multiple publicly-traded life sciences companies will be invaluable to NewAmsterdam ..."
01/17/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"NewAmsterdam Announces Positive Results from ROSE2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy"
01/11/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
01/09/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "NewAmsterdam Pharma Company N.V. Corporate Presentation",
"NewAmsterdam Pharma Company N.V. Corporate Presentation"
12/19/2022 6-K Quarterly results
11/23/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Business Combination Agreement, by and among Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., NewAmsterdam Pharma Company N.V. (f/k/a NewAmsterdam Pharma Company B.V.) and NewAmsterdam Pharma Investment Corporation",
"NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential Preferred Therapy for High Risk Cardiovascular Disease Patients"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy